DXVX is developing a medical data platform using AI technology from LG CNS and Google.
DXVX announced on the 18th that it recently signed a joint development contract for a medical data platform utilizing Google’s platform and AI technology through LG CNS. This is LG CNS’s first collaboration with a domestic pharmaceutical bio company.
Through this joint development, DXVX plans to launch an AI-based digital medical data platform. LG CNS and Google DeepMind will provide the AI and big data technologies necessary for building the platform. LG CNS is a partner and major service provider of Google Cloud.
DXVX plans to expand its service sales network to the global market, including new drug developers and pharmaceutical companies, medical institutions, and research institutes that require specific genomic information or analysis, through the cloud-based medical data platform.
DXVX holds the largest domestic genomic analysis data with over 440,000 cases. This data includes clinical data for medical diagnosis, covering almost all stages of human genomic data and microbiome data such as pre-implantation embryo genome, miscarriage tissue, fetal cell-free DNA, amniotic cells, newborns, adults, and cancer cells.
In particular, since it includes clinical data not only for healthy individuals but also for patient groups, it has high reliability and scalability in discovering biomarkers necessary for cancer cell development stages, rare disease research, infectious disease research, as well as in developing therapeutics and elucidating mechanisms of action.
A DXVX official stated, “Currently, our company is integrating artificial intelligence (AI) into various new drug development projects to increase the success rate of new drug development, while expanding collaboration with domestic and international IT companies to extend related services. This joint development will be a starting point for DXVX to grow into a global medical data company.”
Starting with the joint development, DXVX plans to strengthen collaboration with LG CNS and Google Cloud to develop healthcare solutions that advance the medical data platform.
Meanwhile, recently, global pharmaceutical company GSK invested $300 million (approximately 335 billion KRW) in gene analysis company 23andMe for new drug development using genomic information, and the Korea Bio Association forecasts that the global genomic market will grow to $13.55 billion (15.348 trillion KRW) by 2024.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
